Weight Loss & MetabolicPeer Reviewed
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Authors (11)
Melanie DaviesDiabetes Research Centre, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, Leicester, UK.
Louise FærchNovo Nordisk, Søborg, Denmark.
Ole K JeppesenNovo Nordisk, Søborg, Denmark.
Arash PaksereshtNovo Nordisk, Søborg, Denmark.
Lancet (London, England)
Unknown
Published
Oct 13, 2025
Abstract
Abstract not available - data parsing issue resolved
Keywords
AdultAgedDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsInjections, SubcutaneousMaleMiddle AgedObesityOverweightTreatment OutcomeWeight Loss
Article Metrics
Sourcepubmed
Related Research
Explore more articles in this research category to discover related studies and findings.